Literature DB >> 17350898

Clinical trials in cystic fibrosis.

Gerd Döring1, J Stuart Elborn, Marie Johannesson, Hugo de Jonge, Matthias Griese, Alan Smyth, Harry Heijerman.   

Abstract

In patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, the current status of drug development in CF is discussed and future directions highlighted. Methods for pre-clinical testing of drugs with potential activity in CF patients including relevant animal models are described. Study design options for phase II and phase III studies involving CF patients are provided, including required patient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatory issues for licensing new therapies for CF patients are discussed, including new directives of the European Union and the structure of a European clinical trial network for clinical studies involving CF patients is proposed.

Entities:  

Mesh:

Year:  2007        PMID: 17350898     DOI: 10.1016/j.jcf.2007.02.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  13 in total

Review 1.  Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.

Authors:  Geraint B Rogers; Lucas R Hoffman; Marvin Whiteley; Thomas W V Daniels; Mary P Carroll; Kenneth D Bruce
Journal:  Trends Microbiol       Date:  2010-06-01       Impact factor: 17.079

Review 2.  Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

Authors:  Tacjana Pressler
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

Review 3.  Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.

Authors:  Frédéric Becq
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

Review 4.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Authors:  Alexandra L Quittner; Avani C Modi; Claire Wainwright; Kelly Otto; Jean Kirihara; A Bruce Montgomery
Journal:  Chest       Date:  2009-05-15       Impact factor: 9.410

5.  Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.

Authors:  Ivanka Galeva; Michael W Konstan; Mark Higgins; Gerhild Angyalosi; Florian Brockhaus; Simon Piggott; Karen Thomas; Alexander G Chuchalin
Journal:  Curr Med Res Opin       Date:  2013-06-05       Impact factor: 2.580

6.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

7.  Emerging treatments in cystic fibrosis.

Authors:  Andrew M Jones; Jennifer M Helm
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

8.  Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.

Authors:  Dominique Hubert; Evelyne Le Roux; Thibaud Lavrut; Benoit Wallaert; Philippe Scheid; Dominique Manach; Dominique Grenet; Isabelle Sermet-Gaudelus; Sophie Ramel; Claire Cracowski; Anne Sardet; Nathalie Wizla; Eric Deneuville; Rodolphe Garraffo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

Review 9.  Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Niels Høiby
Journal:  BMC Med       Date:  2011-04-04       Impact factor: 8.775

Review 10.  Cystic Fibrosis Human Organs-on-a-Chip.

Authors:  Herbert Luke Ogden; Hoyeol Kim; Kathryn A Wikenheiser-Brokamp; Anjaparavanda P Naren; Kyu Shik Mun
Journal:  Micromachines (Basel)       Date:  2021-06-25       Impact factor: 2.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.